Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. Issue 10 (1st September 2021)
- Record Type:
- Journal Article
- Title:
- Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. Issue 10 (1st September 2021)
- Main Title:
- Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
- Authors:
- Bai, Bing
Arutyunova, Elena
Khan, Muhammad Bashir
Lu, Jimmy
Joyce, Michael A.
Saffran, Holly A.
Shields, Justin A.
Kandadai, Appan Srinivas
Belovodskiy, Alexandr
Hena, Mostofa
Vuong, Wayne
Lamer, Tess
Young, Howard S.
Vederas, John C.
Tyrrell, D. Lorne
Lemieux, M. Joanne
Nieman, James A. - Abstract:
- Abstract : This article describes peptidomimetic SARS-CoV-2 3CL pro inhibitors with a nitrile warhead with in vitro antiviral inhibition. Superior selectivity was observed for the nitrile warhead compared to the aldehyde against 3 human cathepsins (B, S and L). Abstract : Tragically, the death toll from the COVID-19 pandemic continues to rise, and with variants being observed around the globe new therapeutics, particularly direct-acting antivirals that are easily administered, are desperately needed. Studies targeting the SARS-CoV-2 3CL protease, which is critical for viral replication, with different peptidomimetics and warheads is an active area of research for development of potential drugs. To date, however, only a few publications have evaluated the nitrile warhead as a viral 3CL protease inhibitor, with only modest activity reported. This article describes our investigation of P3 4-methoxyindole peptidomimetic analogs with select P1 and P2 groups with a nitrile warhead that are potent inhibitors of SARS-CoV-2 3CL protease and demonstrate in vitro SARS-CoV-2 antiviral activity. A selectivity for SARS-CoV-2 3CL protease over human cathepsins B, S and L was also observed with the nitrile warhead, which was superior to that with the aldehyde warhead. A co-crystal structure with SARS-CoV-2 3CL protease and a reversibility study indicate that a reversible, thioimidate adduct is formed when the catalytic sulfur forms a covalent bond with the carbon of the nitrile. This effortAbstract : This article describes peptidomimetic SARS-CoV-2 3CL pro inhibitors with a nitrile warhead with in vitro antiviral inhibition. Superior selectivity was observed for the nitrile warhead compared to the aldehyde against 3 human cathepsins (B, S and L). Abstract : Tragically, the death toll from the COVID-19 pandemic continues to rise, and with variants being observed around the globe new therapeutics, particularly direct-acting antivirals that are easily administered, are desperately needed. Studies targeting the SARS-CoV-2 3CL protease, which is critical for viral replication, with different peptidomimetics and warheads is an active area of research for development of potential drugs. To date, however, only a few publications have evaluated the nitrile warhead as a viral 3CL protease inhibitor, with only modest activity reported. This article describes our investigation of P3 4-methoxyindole peptidomimetic analogs with select P1 and P2 groups with a nitrile warhead that are potent inhibitors of SARS-CoV-2 3CL protease and demonstrate in vitro SARS-CoV-2 antiviral activity. A selectivity for SARS-CoV-2 3CL protease over human cathepsins B, S and L was also observed with the nitrile warhead, which was superior to that with the aldehyde warhead. A co-crystal structure with SARS-CoV-2 3CL protease and a reversibility study indicate that a reversible, thioimidate adduct is formed when the catalytic sulfur forms a covalent bond with the carbon of the nitrile. This effort also identified efflux as a property limiting antiviral activity of these compounds, and together with the positive attributes described these results provide insight for further drug development of novel nitrile peptidomimetics targeting SARS-CoV-2 3CL protease. … (more)
- Is Part Of:
- RSC medicinal chemistry. Volume 12:Issue 10(2021)
- Journal:
- RSC medicinal chemistry
- Issue:
- Volume 12:Issue 10(2021)
- Issue Display:
- Volume 12, Issue 10 (2021)
- Year:
- 2021
- Volume:
- 12
- Issue:
- 10
- Issue Sort Value:
- 2021-0012-0010-0000
- Page Start:
- 1722
- Page End:
- 1730
- Publication Date:
- 2021-09-01
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://www.rsc.org/ ↗
https://www.rsc.org/journals-books-databases/about-journals/rsc-medicinal-chemistry ↗ - DOI:
- 10.1039/d1md00247c ↗
- Languages:
- English
- ISSNs:
- 2632-8682
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8036.751550
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26875.xml